INCORPORATION BY REFERENCE
This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576, 333-254101, and 333-261550) and Form F-3 (Registration Numbers 333-209336, 333-211511, 333-216882, 333-223134, 333-225284 and 333-256571) of Ascendis Pharma A/S (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
Closing of Warrant Exercise Window
On March 30, 2022, an exercise window closed for the Company’s outstanding warrants exercisable for the Company’s ordinary shares, nominal value DKK 1. In connection with the exercises of certain of such warrants during this exercise window, the Company registered aggregate share capital increases of nominal DKK 20,709 with the Danish Business Authority, corresponding to an aggregate increase in the Company’s share capital to nominal DKK 56,958,391 through the issuance of 20,709 ordinary shares against average cash consideration of approximately USD $20.69 per share, based on the DKK-USD exchange rate on March 30, 2022. The Company’s articles of association were amended accordingly and are attached hereto as Exhibit 1.1.
Exhibits
